The future of cardiovascular toxicology lies in advancing our understanding of mechanistic pathways and improving risk assessment models. Emerging technologies, such as high-throughput screening and in silico modeling, offer new opportunities for discovery and innovation. Additionally, personalized medicine approaches can provide insights into individual susceptibility and tailor interventions accordingly.
